STATEMENT: StimuSIL about to close an investment round of 1.6 million euros in which it is still possible to invest

Spain, May 26, 2023.

The Spanish Startup specialized in the creation of medical devices for the treatment of androgenic alopecia, is in the final phase to close a round of 1.6 million euros on the online equity crowdfunding platform CapitalCell

Equity crowdfunding is a collective financing formula through the Internet where a group of investors participate in a process of capital increase of a company and receive in exchange a certain number of shares or social participations of the same. This financing formula offers the possibility that anyone can become an investor in companies with high profitability and social impact that have passed an exclusive analysis to try to reduce investment risks. The Stimusil Startup is led by the Spaniards Pablo and Ana Villalba, Mehmet Kosoglu, an expert in FDA regulation, and Dr. Scott Gerrish, managing to consolidate the intellectual property of their innovations thanks to the exclusive license of a patent from Northwestern University. The StimuSIL device for the treatment of androgenic alopecia (common baldness), have produced promising results that point to an excellent safety and efficacy profile. StimuSIL is the non-invasive alternative to hair transplants thanks to its patented technology, the system StimuSIL's precision technology allows light to reach the hair follicle directly, maximizing benefit. In conventional lasers, most of the light is blocked and lost by the melanin layer of the skin, producing minimal effects. Stimusil's patented technology has been driven by a strategic investment made in 2021 by GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. listed company and leader in the pharmaceutical sector in Türkiye. StimuSIL's target market is the United States with more than 7 million cases diagnosed each year, more and more patients are looking for a solution to restore hair growth discreetly and non-invasively, as an alternative to hair transplants. Dr. Scott Gerrish, StimuSIL Medical Director, said: "Our medical and scientific team is deeply committed to improving the lives of people affected by highly stigmatized hair loss and to continuing to innovate in the field of dermal stimulation. Our Our dedication to research and development allows us to explore effective and safe solutions that can make a real difference in the lives of millions of people around the world." Pablo Villalba will hold an online conference on May 30 to explain all the details about the device, its commercialization plan and how you can join the investment round.

Contact Contact name: Alberto Enguita Contact description: Alberto Enguita Telephone number: 675485024